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Abstract: BACKGROUND The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator,
in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had
received intravenous diuretic therapy is unclear. METHODS In this phase 3, randomized, double-blind,
placebo-controlled trial, we assigned 5050 patients with chronic heart failure (New York Heart Association
class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose, 10 mg once
daily) or placebo, in addition to guideline-based medical therapy. The primary outcome was a composite
of death from cardiovascular causes or first hospitalization for heart failure. RESULTS Over a median of
10.8 months, a primary-outcome event occurred in 897 of 2526 patients (35.5%) in the vericiguat group
and in 972 of 2524 patients (38.5%) in the placebo group (hazard ratio, 0.90; 95% confidence interval [CI],
0.82 to 0.98; P = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%)
in the placebo group were hospitalized for heart failure (hazard ratio, 0.90; 95% CI, 0.81 to 1.00). Death
from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients
(17.5%) in the placebo group (hazard ratio, 0.93; 95% CI, 0.81 to 1.06). The composite of death from
any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group
and in 1032 patients (40.9%) in the placebo group (hazard ratio, 0.90; 95% CI, 0.83 to 0.98; P = 0.02).
Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the
patients in the placebo group (P = 0.12), and syncope occurred in 4.0% of the patients in the vericiguat
group and in 3.5% of the patients in the placebo group (P = 0.30). CONCLUSIONS Among patients
with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart
failure was lower among those who received vericiguat than among those who received placebo. (Funded
by Merck Sharp Dohme [a subsidiary of Merck] and Bayer; VICTORIA ClinicalTrials.gov number,
NCT02861534.).
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BACKGROUND
The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in pa-
tients with heart failure and reduced ejection fraction who had recently been 
hospitalized or had received intravenous diuretic therapy is unclear.
METHODS
In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 
5050 patients with chronic heart failure (New York Heart Association class II, III, 
or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose, 
10 mg once daily) or placebo, in addition to guideline-based medical therapy. The 
primary outcome was a composite of death from cardiovascular causes or first 
hospitalization for heart failure.
RESULTS
Over a median of 10.8 months, a primary-outcome event occurred in 897 of 2526 
patients (35.5%) in the vericiguat group and in 972 of 2524 patients (38.5%) in the 
placebo group (hazard ratio, 0.90; 95% confidence interval [CI], 0.82 to 0.98; 
P = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients 
(29.6%) in the placebo group were hospitalized for heart failure (hazard ratio, 0.90; 
95% CI, 0.81 to 1.00). Death from cardiovascular causes occurred in 414 patients 
(16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group 
(hazard ratio, 0.93; 95% CI, 0.81 to 1.06). The composite of death from any cause 
or hospitalization for heart failure occurred in 957 patients (37.9%) in the 
vericiguat group and in 1032 patients (40.9%) in the placebo group (hazard ratio, 
0.90; 95% CI, 0.83 to 0.98; P = 0.02). Symptomatic hypotension occurred in 9.1% of 
the patients in the vericiguat group and in 7.9% of the patients in the placebo 
group (P = 0.12), and syncope occurred in 4.0% of the patients in the vericiguat 
group and in 3.5% of the patients in the placebo group (P = 0.30).
CONCLUSIONS
Among patients with high-risk heart failure, the incidence of death from cardio-
vascular causes or hospitalization for heart failure was lower among those who 
received vericiguat than among those who received placebo. (Funded by Merck 
Sharp & Dohme [a subsidiary of Merck] and Bayer; VICTORIA ClinicalTrials.gov 
number, NCT02861534.)
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H
eart failure with a reduced ejec-
tion fraction imposes a substantial 
health care burden, particularly among 
patients for whom rehospitalization or urgent 
outpatient treatment for heart failure is warranted 
despite the use of guideline-based medical ther-
apy. New treatment options are desirable in this 
high-risk group, and the prognosis is poor com-
pared with that of patients for whom hospital-
ization within 1 year or urgent treatment for 
heart failure is not warranted.1
Vericiguat, a novel oral soluble guanylate cy-
clase stimulator, enhances the cyclic guanosine 
monophosphate (GMP) pathway by directly stim-
ulating soluble guanylate cyclase through a bind-
ing site independent of nitric oxide, and it sensi-
tizes soluble guanylate cyclase to endogenous 
nitric oxide by stabilizing nitric oxide binding to 
the binding site.2 In a phase 2b dose-finding trial 
involving patients with worsening high-risk heart 
failure and a reduced ejection fraction, vericiguat 
reduced the level of N-terminal pro–B-type natri-
uretic peptide (NT-proBNP).3 In the Vericiguat 
Global Study in Subjects with Heart Failure with 
Reduced Ejection Fraction (VICTORIA), we as-
sessed the efficacy and safety of vericiguat in 
patients with a reduced ejection fraction and 
chronic heart failure with recent decompensated 
heart failure. This population of patients with 
worsening symptoms for which medical attention 
is warranted is at risk for death and hospitaliza-
tion for heart failure.
Me thods
Trial Design and Oversight
VICTORIA was a multinational, randomized, 
double-blind, placebo-controlled trial; the trial 
methods have been described previously.4 The 
executive committee designed the trial with na-
tional leaders from participating countries and 
regions and oversaw operations in collaboration 
with the Canadian VIGOUR Centre and the trial 
cosponsors, Merck and Bayer.4 The trial protocol 
(available with the full text of this article at 
NEJM.org) was approved by regulatory agencies 
in the participating countries and institutional 
review boards or ethics committees at the par-
ticipating sites. An independent data and safety 
monitoring committee evaluated patient safety.
The sponsors participated in the trial design, 
selection of participating centers, site monitor-
ing, and data storage. Analyses were conducted 
by the sponsors and independently replicated at 
the Duke Clinical Research Institute (DCRI). The 
sponsors, the Canadian VIGOUR Centre and the 
DCRI, and the executive committee participated 
in the interpretation of the data. The first author 
had unrestricted access to the data and drafted 
the initial version of the manuscript, which was 
reviewed and edited by all the authors. All the 
authors vouch for the accuracy and completeness 
of the data and for the fidelity of the trial to the 
protocol.
Patient Enrollment
Eligible patients were at least 18 years of age and 
had chronic heart failure (New York Heart As-
sociation [NYHA] functional class II, III, or IV), 
a reduced left ventricular ejection fraction of less 
than 45% within 12 months before randomization, 
and an elevated natriuretic peptide level (deter-
mined at the trial sites) within 30 days before 
randomization. For patients in sinus rhythm, 
the criteria included a plasma B-type natriuretic 
peptide (BNP) level of at least 300 pg per milli-
liter or an NT-proBNP level of at least 1000 pg 
per milliliter. For patients in atrial fibrillation, the 
criteria included a BNP level of at least 500 pg per 
milliliter or an NT-proBNP level of at least 1600 pg 
per milliliter.
Patients also had to have evidence of worsen-
ing heart failure. They were categorized into three 
cohorts based on the timing of the deterioration: 
those hospitalized within 3 months before ran-
domization, those hospitalized 3 to 6 months 
before randomization, and those receiving intra-
venous diuretic therapy, without hospitalization, 
within the previous 3 months.4 The percentage 
of enrolled patients with an estimated glomeru-
lar filtration rate of 15 to 30 ml per minute per 
1.73 m2 of body-surface area was capped at 15%. 
All the patients received guideline-based medi-
cal therapy; the inclusion of patients who were 
receiving sacubitril–valsartan background thera-
py (in countries where it was available) was en-
couraged.
Exclusion criteria included a systolic blood 
pressure of less than 100 mm Hg; concurrent or 
anticipated use of long-acting nitrates, soluble 
guanylate cyclase stimulators, or phosphodies-
terase type 5 inhibitors; and use of intravenous 
inotropes or implantable left ventricular assist 
devices. A full list of inclusion and exclusion cri-
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teria is provided in the Supplementary Appendix, 
available at NEJM.org.
Trial Conduct
All the patients provided informed consent and 
entered a screening period (0 to 30 days), without 
a run-in period, during which adherence to the 
entry criteria was confirmed. Patients were then 
randomly assigned, in a 1:1 ratio, to 2.5 mg of 
vericiguat or matching placebo, within six strata 
based on geographic region and, within North 
America, race. Doses were increased to 5 mg and 
ultimately to the target dose of 10 mg once daily 
in a blinded manner, as guided by evaluation of 
blood pressure and clinical symptoms (see the 
Supplementary Appendix).4 Patients were evalu-
ated at weeks 2 and 4, and every 4 months there-
after until the end of the trial. To enhance the 
likelihood of achieving and maintaining the 
target dose of 10 mg, investigators were encour-
aged to address dosing at each visit according to 
the patient’s blood pressure and symptomatic 
status. The follow-up visit schedule is detailed in 
the protocol.4
Trial Outcomes
The primary outcome was a composite of death 
from cardiovascular causes or first hospitaliza-
tion for heart failure. The secondary outcomes 
were the components of the primary outcome, 
first and subsequent hospitalizations for heart 
failure, a composite of death from any cause or 
first hospitalization for heart failure, and death 
from any cause. Prespecified safety outcomes of 
clinical interest included symptomatic hypoten-
sion and syncope.4 Members of an independent 
clinical-events committee who were unaware of 
the trial-group assignments adjudicated all deaths, 
hospitalizations for cardiovascular causes, and 
urgent visits for heart failure (definitions are pro-
vided in the Supplementary Appendix).
Statistical Analysis
The sample size was determined to provide ad-
equate power for the assessment of the outcome 
of death from cardiovascular causes. The expect-
ed event rate among patients in the placebo group 
at 12 months was 11%. Assuming a hazard ratio 
of 0.80 for the outcome of death from cardiovas-
cular causes, we estimated that a sample of 4872 
patients, with an expected 782 events, would pro-
vide the trial with 80% power. A total of 1561 
primary outcome events were expected. For the 
primary outcome, this sample size was expected 
to provide approximately 98% power. These cal-
culations were performed with the use of the 
log-rank test and a one-sided type I error rate of 
0.025. The data and safety monitoring commit-
tee reviewed the trial on a regular basis. Interim 
futility and efficacy analyses were planned but 
did not occur because of enrollment that was 
more rapid than expected and a higher than an-
ticipated rate of death from cardiovascular causes.
A hierarchical testing strategy was prespeci-
fied for the following secondary outcomes: total 
hospitalizations for heart failure, the composite 
of death from any cause or first hospitalization 
for heart failure, and death from any cause. P val-
ues are reported for the primary outcome and 
for subsequent secondary outcomes until the 
first outcome with a P value of greater than 0.05. 
P values are not reported for the components of 
the primary outcome because these analyses 
were not controlled for multiple comparisons.
Efficacy outcomes were examined in the in-
tention-to-treat population with the use of time-
to-event analyses; data on patients who withdrew 
from the trial or were lost to follow-up were cen-
sored at the last available follow-up time. Analyses 
used stratified log-rank tests with the same strata 
considered for randomization. Hazard ratios and 
associated 95% confidence intervals were obtained 
with the use of stratified Cox regression models. 
Subgroup analyses were conducted using a strat-
ified Cox regression model that included trial 
group and the subgroup variable of interest. The 
outcome of total hospitalizations for heart fail-
ure was analyzed with the use of an Andersen–
Gill model with robust standard errors to account 
for possible correlation among patients who had 
recurrent events.5 Safety analyses included all 
patients who received a trial drug.
Baseline characteristics are summarized as 
means and standard deviations or medians and 
interquartile ranges for continuous variables and 
as counts and percentages for categorical variables. 
All the analyses were conducted with the use of 
SAS software, version 9.4 (SAS Institute).
R esult s
Between September 25, 2016, and December 21, 
2018, a total of 6857 patients were screened in 
42 countries, and 5050 were enrolled at 616 sites 
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(Fig. 1).6 Reasons for exclusion of the other 1807 
patients are provided in the Supplementary Ap-
pendix. A total of 2526 patients were randomly 
assigned to receive vericiguat, and 2524 were as-
signed to receive placebo; 7 patients and 9 patients, 
respectively, did not receive the assigned vericiguat 
or placebo.
The baseline characteristics were well 
matched in the two groups (Table 1 and Table 
S1 in the Supplementary Appendix). The mean 
age of the enrolled patients was 67 years, and 
24% were women. At randomization, two thirds 
of the patients had been enrolled within 3 months 
of their index hospitalization for heart failure, 
40% were classified as having NYHA class III 
heart failure, and the mean ejection fraction was 
29%. The median NT-proBNP level was 2816 pg 
per milliliter, as determined in a central labo-
ratory.
The use of concomitant guideline-based med-
ical therapy was well balanced in the two groups: 
60% of the patients received triple therapy (a beta-
blocker and a mineralocorticoid antagonist com-
bined with either an angiotensin-converting–
enzyme inhibitor, an angiotensin-receptor blocker, 
or sacubitril–valsartan) and 15% received an an-
giotensin–neprilysin inhibitor. Notably, 32% of 
the patients had an implantable cardioverter–
defibrillator, a biventricular pacemaker, or both 
devices. Adherence to the trial drug was greater 
than 80% in 93.8% of the patients in the 
vericiguat group and in 93.4% of the patients in 
the placebo group. The median dose of trial 
medication was 9.2 mg in the vericiguat group 
and 9.2 mg in the placebo group. After approxi-
mately 12 months, 90.3% of the patients were 
receiving the 10-mg target dose (89.2% in the 
vericiguat group and 91.4% in the placebo group).
Figure 1. Screening, Randomization, and Follow-up.
Reasons for exclusion are listed in the Supplementary Appendix. Some patients had more than one reason for 
 exclusion.
5050 Underwent randomization
6857 Patients underwent screening
1807 Were excluded
1805 Did not meet eligibility criteria
2 Had other reason
2526 Were assigned to receive vericiguat
2519 Received vericiguat
7 Did not receive vericiguat
2524 Were assigned to receive placebo
2515 Received placebo
9 Did not receive placebo
610 Discontinued trial regimen
177 Had adverse event
9 Were lost to follow-up
48 Did not adhere to
trial regimen
173 Had vericiguat discontin-
ued by physician
8 Deviated from protocol
195 Decided to discontinue
trial regimen
565 Discontinued trial regimen
159 Had adverse event
11 Were lost to follow-up
49 Did not adhere to
trial regimen
154 Had placebo discontin-
ued by physician
2 Deviated from protocol
190 Decided to discontinue
trial regimen
2526 Were included in the analysis 2524 Were included in the analysis
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Follow-up and Trial Outcomes
During the trial, 610 patients in the vericiguat 
group and 565 patients in the placebo group dis-
continued the trial regimen (Fig. 1). Of these pa-
tients, 195 in the vericiguat group discontinued 
vericiguat and 9 were lost to follow-up, and 190 
patients in the placebo group discontinued placebo 
and 11 were lost to follow-up. Ascertainment for 
the primary outcome was complete for 99.5% 
and 99.6% of potential patient-years of follow-up 
in the vericiguat group and the placebo group, 
respectively. The median follow-up period was 
10.8 months.
Death from cardiovascular causes or first hos-








Mean age — yr 67.5±12.2 67.2±12.2 67.3±12.2
Sex — no. (%)
Male 1921 (76.0) 1921 (76.1) 3842 (76.1)
Female  605 (24.0)  603 (23.9) 1208 (23.9)
Race — no. (%)†
White 1621 (64.2) 1618 (64.1) 3239 (64.1)
Black 123 (4.9) 126 (5.0) 249 (4.9)
Asian  571 (22.6)  561 (22.2) 1132 (22.4)
Other 211 (8.4) 219 (8.7) 430 (8.5)
Geographic region — no. (%)
Eastern Europe  848 (33.6)  846 (33.5) 1694 (33.5)
Western Europe  443 (17.5)  446 (17.7)  889 (17.6)
Asia–Pacific  592 (23.4)  591 (23.4) 1183 (23.4)
Latin America  362 (14.3)  362 (14.3)  724 (14.3)
North America  281 (11.1)  279 (11.1)  560 (11.1)
Index event — no. (%)
Hospitalization for heart failure in previous 3 mo 1673 (66.2) 1705 (67.6) 3378 (66.9)
Hospitalization for heart failure in previous 3–6 mo  454 (18.0)  417 (16.5)  871 (17.2)
Intravenous diuretic for heart failure (without hos-
pitalization) in previous 3 mo
 399 (15.8)  402 (15.9)  801 (15.9)
Mean body-mass index‡ 27.7±5.8 27.9±6.1 27.8±5.9
Mean ejection fraction at screening — % 29.0±8.3 28.8±8.3 28.9±8.3
Ejection fraction <40% — no. (%) 2158 (85.8) 2158 (85.6) 4316 (85.7)
NYHA class — no./total no. (%)
I 0   2/2523 (0.1)    2/5046 (<0.1)
II 1478/2523 (58.6) 1497/2523 (59.3) 2975/5046 (59.0)
III 1010/2523 (40.0)  993/2523 (39.4) 2003/5046 (39.7)
IV  35/2523 (1.4)  31/2523 (1.2)  66/5046 (1.3)
Mean time from initial diagnosis of heart failure with 
reduced ejection fraction to randomization — yr
4.7±5.5 4.8±5.4 4.8±5.4
*  Plus–minus values are means ±SD. Data were missing for the following characteristics: body-mass index (for 17 patients in the vericiguat 
group and 20 patients in the placebo group), ejection fraction (for 10 patients in the vericiguat group and 4 patients in the placebo group), 
and time from initial diagnosis of heart failure with reduced ejection fraction to randomization (for 1 patient in the vericiguat group and  
3 patients in the placebo group). Percentages may not total 100 because of rounding. NYHA denotes New York Heart Association.
†  Race was reported by the patient. In North America, there were 62 black patients in the vericiguat group and 61 in the placebo group.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
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pitalization for heart failure (the primary outcome) 
occurred in 897 patients (35.5%) in the vericiguat 
group and in 972 patients (38.5%) in the placebo 
group (hazard ratio, 0.90; 95% confidence interval 
[CI], 0.82 to 0.98; P = 0.02) (Fig. 2A and Table 2). 
Death from cardiovascular causes occurred in 
Figure 2. Estimates of the Cumulative Incidence of the Primary Outcome and Secondary Outcomes.
The primary outcome was a composite of death from cardiovascular causes or first hospitalization for heart failure (Panel A). Shown are 
the cumulative incidences of death from cardiovascular causes (Panel B), first hospitalization for heart failure (Panel C), and the second-
ary composite outcome (death from any cause or first hospitalization for heart failure) (Panel D). The inset in each panel shows the same 
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Hazard ratio, 0.90 (95% CI, 0.83–0.98)
Vericiguat
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414 patients (16.4%) in the vericiguat group and 
in 441 patients (17.5%) in the placebo group (haz-
ard ratio, 0.93; 95% CI, 0.81 to 1.06) (Fig. 2B and 
Table 2). Hospitalization for heart failure occurred 
in 691 patients (27.4%) in the vericiguat group 
and in 747 patients (29.6%) in the placebo group 
(hazard ratio, 0.90; 95% CI, 0.81 to 1.00) (Fig. 2C 
and Table 2).
There were 1223 total hospitalizations (first 
and recurrent events) for heart failure (38.3 events 
per 100 patient-years) in the vericiguat group and 
1336 total hospitalizations (42.4 events per 100 
patient-years) in the placebo group (hazard ratio, 
0.91; 95% CI, 0.84 to 0.99; P = 0.02) (Table 2). 
Death from any cause or first hospitalization for 
heart failure (a composite secondary outcome) 
occurred in 957 patients (37.9%) in the vericiguat 
group and in 1032 patients (40.9%) in the pla-
cebo group (hazard ratio, 0.90; 95% CI, 0.83 to 
0.98; P = 0.02) (Fig. 2D and Table 2). Death from 
any cause occurred in 512 patients (20.3%) in 
the vericiguat group and in 534 patients (21.2%) 
in the placebo group (hazard ratio, 0.95; 95% CI, 
0.84 to 1.07; P = 0.38) (Fig. S1 and Table 2). The 
effect of vericiguat on the primary outcome was 
consistent across most prespecified subgroups 
(including patients receiving sacubitril–valsartan), 
except in the subgroups defined according to age 
and NT-proBNP level (Fig. 3).
Safety
Serious adverse events occurred in 32.8% of the 
patients in the vericiguat group and in 34.8% of 
the patients in the placebo group (Table S2). Ad-
verse events (serious and nonserious) occurred in 
80.5% of the patients receiving vericiguat and in 
Table 2. Primary and Secondary Outcomes.*
Outcome
Vericiguat 
 (N = 2526)
Placebo 
 (N = 2524)
Hazard Ratio 






Primary composite outcome and 
components
Death from cardiovascular causes or 
first hospitalization for heart 
failure
897 (35.5) 33.6 972 (38.5) 37.8 0.90 (0.82–0.98) 0.02
Death from cardiovascular 
causes§
206 (8.2) 225 (8.9)
Hospitalization for heart failure 691 (27.4) 747 (29.6)
Secondary outcomes
Death from cardiovascular causes 414 (16.4) 12.9 441 (17.5) 13.9 0.93 (0.81–1.06)
Hospitalization for heart failure 691 (27.4) 25.9 747 (29.6) 29.1 0.90 (0.81–1.00)
Total hospitalizations for heart 
failure¶
1223 38.3 1336 42.4 0.91 (0.84–0.99) 0.02
Secondary composite outcome and 
components
Death from any cause or first hospi-
talization for heart failure
957 (37.9) 35.9 1032 (40.9) 40.1 0.90 (0.83–0.98) 0.02
Death from any cause§ 266 (10.5) 285 (11.3)
Hospitalization for heart failure 691 (27.4) 747 (29.6)
Death from any cause 512 (20.3) 16.0 534 (21.2) 16.9 0.95 (0.84–1.07) 0.38
*  Data shown are through the primary analysis cutoff date (June 18, 2019). For patients with multiple events, only the first event that contrib-
uted to the composite outcome is counted. CI denotes confidence interval.
†  Hazard ratios (vericiguat as compared with placebo) and confidence intervals were calculated with the use of Cox proportional-hazards 
models controlling for stratification factors (defined according to geographic region and race).
‡  P values were calculated by means of a stratified log-rank test with stratification factors defined according to geographic region and race.
§  Deaths included in the primary and secondary composite outcomes were not preceded by a hospitalization for heart failure.
¶  Patients could have been hospitalized more than once.
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81.0% of the patients receiving placebo (Table S3). 
The prespecified adverse events of clinical inter-
est were symptomatic hypotension and syncope. 
Symptomatic hypotension occurred in 9.1% of 
the patients in the vericiguat group and in 7.9% 
of the patients in the placebo group (P = 0.12), 
and syncope occurred in 4.0% of patients in the 
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placebo group (P = 0.30) (Table S4). Baseline sys-
tolic blood pressure was 121.2 mm Hg in the 
vericiguat group and 121.5 mm Hg in the placebo 
group. Systolic blood pressure declined slightly 
in both groups over the first 16 weeks (more so 
in the vericiguat group than in the placebo group) 
and returned to baseline thereafter (Fig. S2).
Anemia developed in more patients in the 
vericiguat group than in the placebo group (in 7.6% 
and 5.7%); of these cases, 1.6% (in the vericiguat 
group) and 0.9% (in the placebo group) were con-
sidered serious adverse events. The baseline mean 
(±SD) hemoglobin level was 13.3±1.9 g per deci-
liter in the vericiguat group and 13.4±1.9 g per 
deciliter in the placebo group, and the change 
from baseline in the hemoglobin level at week 16 
was −0.38±1.27 g per deciliter and −0.14±1.30, 
respectively.
Discussion
In this trial involving patients with chronic heart 
failure and a reduced ejection fraction who had 
worsening symptoms for which hospitalization 
or urgent treatment was warranted, the incidence 
of the composite of death from cardiovascular 
causes or hospitalization for heart failure was 
lower with vericiguat than with placebo. The dif-
ference favoring vericiguat appeared after ap-
proximately 3 months of treatment and persisted 
throughout the trial. The 10% relative difference 
between the groups in the primary composite 
outcome in this high-risk population at a medi-
an follow-up of 10.8 months translated into an 
absolute event-rate reduction of 4.2 events per 
100 patient-years. Based on this absolute risk re-
duction, the number needed to treat with vericiguat 
for 1 year to prevent a primary-outcome event is 
approximately 24 patients (or 28 patients accord-
ing to the difference in 12-month Kaplan–Meier 
estimates). This outcome occurred in patients who 
were receiving guideline-based medical therapy.
An analysis of the components of the primary 
outcome revealed that the incidence of hospital-
ization for heart failure was lower with vericiguat 
than with placebo, and the incidence of death 
from cardiovascular causes was possibly lower. 
There was no significant between-group differ-
ence in the incidence of death from any cause. 
However, it is noteworthy that the prespecified 
events were accrued earlier than expected, thereby 
leaving a relatively short exposure time and po-
tentially limiting our assessment of a later effect.
It is of interest to compare the current trial 
population with those of two previous trials in-
volving patients with heart failure and a reduced 
ejection fraction. In the PARADIGM-HF (Prospec-
tive Comparison of Angiotensin Receptor–Nepri-
lysin Inhibitor with Angiotensin-Converting-
Enzyme Inhibitors to Determine Impact on Global 
Mortality and Morbidity in Heart Failure) and 
the DAPA-HF (Dapagliflozin and Prevention of 
Adverse Outcomes in Heart Failure) trials, 25% 
and 32% of the patients, respectively, had either 
NYHA class III or IV heart failure, as compared 
with 41% of the patients in VICTORIA. Similarly, 
the median NT-proBNP values were 1608 and 
1437 pg per milliliter in PARADIGM-HF and 
DAPA-HF, respectively, as compared with 2816 pg 
per milliliter in VICTORIA.7-9 These differences 
probably account for the 33.6% annualized rate of 
the primary composite outcome in the vericiguat 
group in our trial; this is more than two times 
as high as that seen in the two comparator tri-
als.9,10 Although both of these trials showed 
more substantial relative reductions in the pri-
mary composite outcome of VICTORIA (a com-
posite of death from cardiovascular causes or 
first hospitalization for heart failure), the annual-
ized reductions in absolute risk are similar.11
A review of the treatment effect across pre-
specified subgroups indicates a generally consis-
tent treatment effect, even in subgroups defined 
by the index heart failure event. Whether the pa-
tients with very elevated NT-proBNP levels are a 
subgroup with heart failure that is too advanced 
Figure 3 (facing page). Primary Outcome in Prespecified 
Subgroups.
The primary outcome was a composite of death from 
cardiovascular causes or first hospitalization for heart 
failure. Race was reported by the patient. Data were 
missing for the following subgroups: New York Heart 
Association (NYHA) class (for 1 patient in the vericiguat 
group and 1 patient in the placebo group), use of sacu-
bitril–valsartan (for 3 patients in the vericiguat group 
and 1 patient in the placebo group), estimated glomeru-
lar filtration rate (GFR) (for 16 patients in the vericiguat 
group and 17 patients in the placebo group), N-terminal 
pro–B-type natriuretic peptide (NT-proBNP) level (for 
36 patients in the vericiguat group and 51 patients in the 
placebo group), and ejection fraction (for 5 patients in 
the vericiguat group and 4 patients in the placebo group).
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for a favorable effect of vericiguat rather than the 
play of chance is uncertain. Other high-risk base-
line characteristics that affect treatment responses, 
such as advanced age and diminished renal func-
tion, probably coexist within this subgroup and 
other subgroups. Because of the small number 
of patients who were already receiving inhibitors 
of sodium–glucose cotransporter 2, we cannot 
address the potential incremental role of vericiguat 
in this population.
As expected, symptomatic hypotension and 
syncope were more common in the patients re-
ceiving vericiguat than in those receiving placebo. 
At the initial 16-week follow-up visit, the hemo-
globin level was slightly lower in the patients 
receiving vericiguat than in those receiving pla-
cebo, as previously reported for this class of 
agents.12 The overall frequency of adverse events 
was similar in the two groups, as were adverse 
events related to renal function or electrolyte 
balance.
Modulation of the nitric oxide–soluble gua-
nylate cyclase pathway that generates cyclic GMP 
is essential for normal cardiovascular function. 
In heart failure, endothelial dysfunction and re-
active oxygen species reduce nitric oxide bioavail-
ability, resulting in relative deficiency of soluble 
guanylate cyclase and reduced cyclic GMP genera-
tion.13 In contrast to the therapeutic approach of 
antagonizing counterregulatory neurohormonal 
pathways characteristic of many other therapies 
for heart failure, vericiguat enhances the cyclic 
GMP pathway by directly stimulating soluble 
guanylate cyclase through a binding site inde-
pendent of nitric oxide and by sensitizing soluble 
guanylate cyclase to endogenous nitric oxide.2 
This selectivity in cyclic GMP generation does 
not occur with nitrates or phosphodiesterase 
inhibitors.
Heart failure remains a major burden, with 
many patients facing a considerable risk of death 
or recurrent hospitalization.14 Projections suggest 
that the prevalence will continue to increase, and 
more than 8 million people in the United States 
are estimated to have heart failure by 2030, ap-
proximately half of whom will have reduced ejec-
tion fraction.15 Adherence to medications is fre-
quently challenging because of side effects, 
resulting in decreased adherence to guideline-
recommended therapies over 2 to 4 months after 
discharge.16,17 Given these factors, it is crucial for 
patients to have treatment options. This is espe-
cially true in the emerging era of precision medi-
cine, since patients and providers are searching 
for personalized treatment based on anticipated 
benefits, a favorable side-effect profile, value, 
and ease of use.18 In this regard, it is noteworthy 
that there was greater than 89% adherence to the 
target 10-mg dose of vericiguat after 12 months 
in our trial.
In conclusion, we conducted a multinational 
clinical trial involving patients with chronic heart 
failure who had evidence of clinical worsening. 
Patients were randomly assigned to receive either 
the oral soluble guanylate cyclase stimulator 
vericiguat or placebo. At a median of 10.8 months, 
the incidence of the primary outcome of death 
from cardiovascular causes or first hospitalization 
for heart failure was significantly lower with 
vericiguat than with placebo.
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